Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.24
ULGX's Cash to Debt is ranked lower than
56% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. ULGX: 0.24 )
ULGX' s 10-Year Cash to Debt Range
Min: 0.24   Max: No Debt
Current: 0.24

Equity to Asset -0.17
ULGX's Equity to Asset is ranked lower than
60% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ULGX: -0.17 )
ULGX' s 10-Year Equity to Asset Range
Min: -0.17   Max: 0.96
Current: -0.17

-0.17
0.96
F-Score: 3
Z-Score: -15.56
M-Score: -3.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -23.64
ULGX's Operating margin (%) is ranked higher than
50% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. ULGX: -23.64 )
ULGX' s 10-Year Operating margin (%) Range
Min: -1950   Max: 12.1
Current: -23.64

-1950
12.1
Net-margin (%) -25.87
ULGX's Net-margin (%) is ranked higher than
50% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. ULGX: -25.87 )
ULGX' s 10-Year Net-margin (%) Range
Min: -1900   Max: 21.22
Current: -25.87

-1900
21.22
ROE (%) -1021.90
ULGX's ROE (%) is ranked lower than
60% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. ULGX: -1021.90 )
ULGX' s 10-Year ROE (%) Range
Min: -1021.9   Max: 13.74
Current: -1021.9

-1021.9
13.74
ROA (%) -34.26
ULGX's ROA (%) is ranked lower than
53% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. ULGX: -34.26 )
ULGX' s 10-Year ROA (%) Range
Min: -110.2   Max: 12.52
Current: -34.26

-110.2
12.52
ROC (Joel Greenblatt) (%) -169.78
ULGX's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. ULGX: -169.78 )
ULGX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -751.25   Max: 64.33
Current: -169.78

-751.25
64.33
Revenue Growth (%) -7.80
ULGX's Revenue Growth (%) is ranked higher than
55% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ULGX: -7.80 )
ULGX' s 10-Year Revenue Growth (%) Range
Min: -20.9   Max: 108
Current: -7.8

-20.9
108
EBITDA Growth (%) 17.00
ULGX's EBITDA Growth (%) is ranked higher than
89% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. ULGX: 17.00 )
ULGX' s 10-Year EBITDA Growth (%) Range
Min: -80.1   Max: 17
Current: 17

-80.1
17
EPS Growth (%) 11.90
ULGX's EPS Growth (%) is ranked higher than
83% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. ULGX: 11.90 )
ULGX' s 10-Year EPS Growth (%) Range
Min: -54.1   Max: 11.9
Current: 11.9

-54.1
11.9
» ULGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ULGX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 0.20
ULGX's P/S is ranked higher than
99% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. ULGX: 0.20 )
ULGX' s 10-Year P/S Range
Min: 0.18   Max: 9.56
Current: 0.2

0.18
9.56
EV-to-EBIT 31.30
ULGX's EV-to-EBIT is ranked lower than
57% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. ULGX: 31.30 )
ULGX' s 10-Year EV-to-EBIT Range
Min: 14.3   Max: 430.2
Current: 31.3

14.3
430.2

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.20
ULGX's Price/Median PS Value is ranked higher than
98% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. ULGX: 0.20 )
ULGX' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 122.73
Current: 0.2

0.18
122.73
Forward Rate of Return (Yacktman) -71.29
ULGX's Forward Rate of Return (Yacktman) is ranked higher than
50% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. ULGX: -71.29 )
ULGX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.1   Max: -4.3
Current: -71.29

-13.1
-4.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Urologix Inc. was incorporated in Minnesota. The company develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from non-cancerous prostate enlargement also known as benign prostatic hyperplasia (BPH). These therapies use proprietary technology in the treatment of BPH, a disease that affects more than 30 million men worldwide and is the common prostate problem for men over 50. It markets both the Cooled ThermoTherapy (CTT) product line and the Prostiva Radio Frequency (RF) Therapy System. It acquired the exclusive worldwide license to the Prostiva RF Therapy System in September 2011. These two technologies are designed to be used by urologists in their offices without placing their patients under general anesthesia. CTT uses a flexible catheter to deliver targeted microwave energy combined with a unique cooling mechanism that protects healthy urethral tissue and enhances patient comfort to provide safe, effective, lasting relief from BPH voiding symptoms by the thermal ablation of hyperplastic prostatic tissue surrounding the urethra. The proprietary Prostiva RF Therapy System delivers radio frequency energy directly into the prostate through the use of insulated electrodes deployed from a transurethral scope, ablating targeted prostatic tissue under the direct visualization of the urologist. These focal ablations reduce constriction of the urethra, thereby relieving BPH voiding symptoms. These two proven technologies have slightly different, yet complementary, patient indications and providing them to its urologist customers enables them to treat a wide range of patients in their office.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide